SteadyMed to Present at the 2017 JMP Securities Life Sciences Conference
June 13 2017 - 8:30AM
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company
focused on the development of drug product candidates to treat
orphan and high-value diseases with unmet parenteral delivery
needs, today announced that Jonathan M. N. Rigby, President and
Chief Executive Officer, will present at the 2017 JMP Securities
Life Science Conference on Tuesday, June 20, 2017. During the
presentation, Mr. Rigby will provide an overview and update on the
company's business including the development of its lead drug
product candidate Trevyent®, that is in development to treat
Pulmonary Arterial Hypertension (PAH).
Date: Tuesday, June 20,
2017Time: 1:30 pm ETLocation: New
York, NY
An audio webcast of the Company’s presentation
will be available online at SteadyMed’s website www.steadymed.com.
A replay of the presentation will be available for 90 days.
Investors attending the conference who are
interested in meeting with Mr. Rigby may request a meeting by
contacting their JMP Securities representative, or Lee Roth of The
Ruth Group at lroth@theruthgroup.com.
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical
company focused on the development of drug products to treat orphan
and high value diseases with unmet parenteral delivery needs. The
company's lead drug product candidate is Trevyent, a development
stage drug product that combines SteadyMed's pre-filled, sterile,
single use, disposable, PatchPump® infusion system, with
treprostinil, a vasodilatory prostacyclin analogue to treat
pulmonary arterial hypertension (PAH). SteadyMed intends to
commercialize Trevyent in the U.S. and has signed an exclusive
license and supply agreement with Cardiome Pharma Corp. for the
commercialization of Trevyent in Europe, Canada and the Middle
East. SteadyMed has offices in San Ramon, California and Rehovot,
Israel. For additional information about SteadyMed please visit
www.steadymed.com.
Contacts:
Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com
The Ruth Group
Lee Roth
(646) 536-7012
lroth@theruthgroup.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Apr 2023 to Apr 2024